Australian respiratory imaging tech company 4DMedical Limited has secured $1.1 million in funding from the Clinical Translation and Commercialisation Medtech (CTCM) program, an initiative of the Medical Research Future Fund delivered by MTPConnect.
The funding program, backed by the Medical Device Partnering Program and the Medical Technology Association of Australia, will expand the capability of its lung scanner, XV Scanner, beyond ventilation to include the measurement of blood flow, 4DMedical said in an ASX announcement.
Launched in 2022, XV Scanner, the world’s first and only dedicated lung scanner, is designed to provide doctors and patients with unprecedented and highly visual insight into lung function by integrating 4Dmedical’s XV Technology into a purpose-built platform.
The additional perfusion capability will strengthen 4DMedical’s position as a leader in non-invasive lung diagnostics by providing detailed quantitative data on respiratory function via a single scan that has many advantages over existing modalities.
“Combining both functional components of airflow and blood flow into a single analytical process represents a dramatic advancement in respiratory healthcare, providing the ideal test for phenotyping, early detection and evaluation of specific treatment responses for high-impact lung diseases such as Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, pulmonary hypertension and pulmonary embolism,” said Andreas Fouras, chief executive officer and founder of 4DMedical.
The funding will accelerate the final stage of the company’s product pipeline. Once complete, doctors and patients will be able to order detailed ventilation and perfusion maps of pulmonary function where the underlying images are acquired using X-ray, CT, and 4DMedical’s purpose-built XV Scanner.
ASX-listed 4DMedical Limited is a global medical technology company that helps physicians understand regional airflow in the lungs and identify respiratory deficiencies earlier through its flagship patented XV Technology.
The proprietary technology powers 4DMedical’s XV Lung Ventilation Analysis Software— the first modality to dynamically quantify ventilation throughout the lungs and its Computed Tomography-e\nabled counterpart software, CT LVAS.
